Trial reportAIDS (London, England)2025
Exploring the PREVENT HF score and myocardial function among persons with HIV.
Trial report in AIDS (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02740179 (Mineralocorticoid Receptor Antagonism for Cardiovascular Health in HIV--The MIRACLE HIV Study), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Mineralocorticoid Receptor Antagonism for Cardiovascular Health in HIV--The MIRACLE HIV Study
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectivePersons with HIV (PWH) are at risk for myocardial structural changes, which can progress to diastolic dysfunction and heart failure with preserved ejection fraction (HFpEF). We explored the AHA PREVENT HF (Predicting Risk of cardiovascular disease EVENTs for Heart Failure) risk score in relation to cardiac magnetic resonance (CMR) imaging.
designThis cross-sectional study included 37 PWH on ART, ages 40-65, without known cardiovascular disease (CVD) who underwent CMR.
methodsThe risk score was assessed using the AHA PREVENT HF calculator. Scores were correlated to variables on CMR that are known indicators of subclinical myocardial dysfunction [left atrial volume index (LAVI), global longitudinal strain (GLS), and left ventricular mass index (LVMI)] and inflammation [extracellular volume (ECV) and longitudinal relaxation (T1)].
resultsPWH were age 55 (6) years [mean (SD)], predominantly male (76%) and white (57%) with BMI in the obese (≥30 kg/m 2 ) range: 31 (5) kg/m 2 . Median PREVENT HF score was 2.6 (1.4, 4.1)% [median (25th, 75th)]. The PREVENT HF score correlated to LAVI ( ρ = 0.35, P = 0.04), T1 ( ρ = 0.35, P = 0.04), interleukin (IL)-6 ( ρ = 0.36, P = 0.03) and NT-proBNP ( ρ = 0.42, P = 0.01). Risk scores were higher for those meeting clinical cutoffs LAVI >34 ml/m 2 and T1 ≥1250 ms. For predicting LAVI >34 ml/m 2 , a PREVENT HF score of 2.5 was the optimal cutoff [sensitivity 85%, specificity 65%, AUROC 0.769 ( P < 0.05)]. In predicting T1 ≥1250 ms, a PREVENT HF score of 3.6 was the optimal cutoff [71% sensitivity, 95% specificity, AUROC 0.727 ( P < 0.05)].
conclusionThe PREVENT HF score related to indices of altered myocardial structure and inflammation among asymptomatic PWH with subclinical disease. These data begin to inform us about the utility of PREVENT HF score using radiographic findings, though more studies are needed among PWH to validate its use as a prediction tool. CLINICAL TRIALS REGISTRATION: NCT02740179.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.